Hints and tips:
Related Special Reports
...He said Novo Nordisk was facing a “similar challenge” as some of the companies selling advanced therapies....
...Danish drugmaker Novo Nordisk has been “surprised” by the readiness of European consumers to pay for weight-loss drugs from their own pockets, as the region’s largest company invests in new supply to meet...
...The US Food and Drug Administration says there is a shortage of Novo Nordisk’s and Eli Lilly’s diabetes drugs, while Belgium has banned the off-label use of Novo Nordisk’s diabetes drug for obesity treatments...
...Last year, it launched reNEW, the Novo Nordisk Foundation Center for Stem Cell Medicine, supporting research in Denmark, Australia and the Netherlands....
...Medical research cited by the Centers for Disease Control and Prevention said obesity-related healthcare accounts for more than $170bn in excess medical costs on an annual basis....
...Denmark’s weight loss drugmaker Novo Nordisk is the best known example....
...Novo Nordisk and Eli Lilly have struggled to keep up with soaring demand for obesity treatments....
...One of the drugs, Novo Nordisk’s Wegovy, received approval in the US for prevention of heart attacks and other cardiovascular events in March....
...“Today’s approval addresses an unmet medical need,” said John Sharretts, director of the diabetes and obesity division in the FDA’s Center for Drug Evaluation and Research in a statement....
...Vertex “is probably going to be one of the fastest-growing top lines outside of the weight-loss drugmakers [Eli] Lilly and Novo [Nordisk],” predicts Debjit Chattopadhyay, a healthcare analyst at Guggenheim...
...Dr Domenica Rubino, director of the Washington Center for Weight Management and Research, who also served as an investigator on a trial for the Novo Nordisk drug Wegovy, said patients had quite different...
...The initial result was “out of this world”, says Martin Lange, executive vice-president of development for Novo Nordisk....
...He added that Novo Nordisk’s and Eli Lilly’s blockbuster diabetes and weight loss drugs Ozempic and Mounjaro could be included on the list in 2027 and 2031 respectively....
...The top five contributors to the fund’s performance last year were Meta Platforms, Microsoft, Novo Nordisk, L’Oréal and IDEXX Laboratories....
...Baras said the GLP-1 drugs from Novo Nordisk and Eli Lilly had been a “fantastic development for the field”....
...Like a similar drug from Novo Nordisk, it targets a brain area that regulates appetite....
...“That [manufacturing] expertise will be important, especially with diabetes, which is more of a primary care market,” said Chen, adding that rivals Lilly and Novo Nordisk have experienced supply issues because...
...Both Novo Nordisk and — if approved — Eli Lilly will face a battle to convince payers to fund the drug....
...I don’t want to spend the next three years closing research centres.”...
...Todd Hobbs, vice-president and diabetes chief medical officer at Novo Nordisk in North America, says the drug took “decades of research”....
...Novo Holdings manages the $60bn portfolio of the Novo Nordisk Foundation, a Danish medical and research charity....
...As diabetic patients have shared horror stories about not being able to afford insulin, Sanofi and rivals Eli Lilly and Novo Nordisk have come under fire for price increases on the essential medicine....
...“Three huge drug companies, which made $14.5bn in profit last year, control 90 per cent of the insulin market,” he says, referring to insulin makers Eli Lilly, Sanofi and Novo Nordisk....
...(FT) News round-up Sanofi beats Novo Nordisk with €3.9bn Ablynx deal (FT) Sanofi/Novo Nordisk: blood money (FT Lex) Dell is considering a sale to VMware in what may be tech’s biggest deal ever (CNBC)...
...However, the two investments being announced today, on top of moves by AstraZeneca to make its headquarters in Cambridge and Novo Nordisk to fund a diabetes research centre in Oxford suggested “we are seeing...
International Edition